{"id":463,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-glucagon-glp-1-research-status-and-material-identity","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","title":{"rendered":"Statut de recherche Survodutide\u00a0: Biologie Dual Glucagon\/GLP-1, essais et identit\u00e9 mat\u00e9rielle"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Survodutide est un double agoniste des r\u00e9cepteurs du glucagon et des r\u00e9cepteurs GLP-1 en d\u00e9veloppement clinique. \u00ab\u00a0Double agoniste\u00a0\u00bb d\u00e9crit la pharmacologie des r\u00e9cepteurs\u00a0; il ne s'agit pas d'un certificat de statut clinique ni d'une preuve que deux mat\u00e9riaux portant le m\u00eame nom court sont \u00e9quivalents.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Ce que montre le dossier<\/h2><ul class=\"wp-block-list\"><li>Les r\u00e9sultats des phases 2 et 3 doivent \u00eatre attribu\u00e9s \u00e0 la formulation et \u00e0 la population \u00e9tudi\u00e9es.<\/li><li>L'article 3 de la phase 2026 d\u00e9crit toujours le survodutide comme \u00e9tant exp\u00e9rimental.<\/li><li>Les contr\u00f4les de s\u00e9quence, de contre-ions, de puret\u00e9, de contenu et d'impuret\u00e9s restent des questions sp\u00e9cifiques aux lots.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\" alt=\"Un scientifique examine les donn\u00e9es d\u2019essais m\u00e9taboliques et deux voies de signalisation des r\u00e9cepteurs\" class=\"wp-image-457\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Illustration \u00e9ditoriale originale utilis\u00e9e pour identifier le th\u00e8me de recherche. Il ne d\u00e9crit pas un lot catalogue, un m\u00e9dicament approuv\u00e9, un r\u00e9sultat de test ou une utilisation clinique.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">La fronti\u00e8re entre l\u2019identit\u00e9 et la preuve<\/h2><p class=\"wp-block-paragraph\">Le programme de phase 2 a \u00e9tabli un signal de dosage, tandis que SYNCHRONIZE-1 a fourni le premier r\u00e9sultat publi\u00e9 sur l'ob\u00e9sit\u00e9 de phase 3. Ces dossiers r\u00e9pondent aux questions de d\u00e9veloppement clinique. Ils ne pr\u00e9cisent pas si un lot du catalogue a la m\u00eame s\u00e9quence, la m\u00eame formulation, le m\u00eame profil d'exposition ou les m\u00eames contr\u00f4les de fabrication.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Profil du r\u00e9cepteur<\/strong><span>R\u00e9cepteur du glucagon + agonisme du r\u00e9cepteur GLP-1<\/span><\/div><div class=\"pim-evidence-row\"><strong>Ancre de donn\u00e9es actuelles<\/strong><span>SYNCHRONIZE-1, NCT06066515<\/span><\/div><div class=\"pim-evidence-row\"><strong>Limite du catalogue<\/strong><span>Aucune d\u00e9duction d\u2019\u00e9quivalence avec la formulation d\u2019essai<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Ce qui appartient au dossier mat\u00e9riel<\/h2><p class=\"wp-block-paragraph\">Pour l'approvisionnement en recherche, enregistrez la s\u00e9quence exacte et la forme mol\u00e9culaire, la teneur en peptides, la m\u00e9thode chromatographique, la confirmation de masse, les informations sur l'eau et les contre-ions, ainsi que toute exigence d'agr\u00e9gation ou d'impuret\u00e9. \u00c9vitez de d\u00e9crire un mat\u00e9riel de recherche comme une intervention clinique sans lien documentaire.<\/p><h2 class=\"wp-block-heading\">R\u00e8gle \u00e9ditoriale<\/h2><p class=\"wp-block-paragraph\">Utilisez le nom exact de l\u2019intervention, le mod\u00e8le, la population et le point final de l\u2019enregistrement cit\u00e9. Ne convertissez pas une association, un m\u00e9canisme, un r\u00e9sultat animal, un dossier de m\u00e9dicament fini approuv\u00e9 ou un test analytique en une all\u00e9gation concernant un lot du catalogue sans rapport.<\/p>","protected":false},"excerpt":{"rendered":"<p>Survodutide est un double agoniste des r\u00e9cepteurs du glucagon et des r\u00e9cepteurs GLP-1 en d\u00e9veloppement clinique. \u00ab\u00a0Double agoniste\u00a0\u00bb d\u00e9crit la pharmacologie des r\u00e9cepteurs\u00a0; il ne s'agit pas d'un certificat de statut clinique ni d'une preuve que deux mat\u00e9riaux portant le m\u00eame nom court sont \u00e9quivalents.<\/p>","protected":false},"author":1,"featured_media":628,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"Phase 2 and phase 3 records; development and identity review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Survodutide Research Status: Trials &amp; Material Identity<\/title>\n<meta name=\"description\" content=\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/survodutide-glucagon-glp-1-research-status-and-material-identity\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity\" \/>\n<meta property=\"og:description\" content=\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/survodutide-glucagon-glp-1-research-status-and-material-identity\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide Research Status: Dual Glucagon\\\/GLP-1 Biology, Trials and Material Identity\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\",\"name\":\"Survodutide Research Status: Trials & Material Identity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-glucagon-glp-1-research-status-and-material-identity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide Research Status: Dual Glucagon\\\/GLP-1 Biology, Trials and Material Identity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Statut de recherche Survodutide\u00a0: essais et identit\u00e9 mat\u00e9rielle","description":"Survodutide est un double agoniste des r\u00e9cepteurs du glucagon et des r\u00e9cepteurs GLP-1 en d\u00e9veloppement clinique. \u00ab\u00a0Double agoniste\u00a0\u00bb d\u00e9crit la pharmacologie des r\u00e9cepteurs\u00a0; ce n'est pas un cer\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","og_locale":"fr_FR","og_type":"article","og_title":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity","og_description":"Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. \u201cDual agonist\u201d describes receptor pharmacology; it is not a cer\u2026","og_url":"https:\/\/nhdbio.com\/fr\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","url":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/","name":"Statut de recherche Survodutide\u00a0: essais et identit\u00e9 mat\u00e9rielle","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Survodutide est un double agoniste des r\u00e9cepteurs du glucagon et des r\u00e9cepteurs GLP-1 en d\u00e9veloppement clinique. \u00ab\u00a0Double agoniste\u00a0\u00bb d\u00e9crit la pharmacologie des r\u00e9cepteurs\u00a0; ce n'est pas un cer\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-glucagon-glp-1-research-status-and-material-identity-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-glucagon-glp-1-research-status-and-material-identity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide Research Status: Dual Glucagon\/GLP-1 Biology, Trials and Material Identity"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=463"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/463\/revisions"}],"predecessor-version":[{"id":513,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/463\/revisions\/513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/628"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}